Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.50 USD
Change Today -0.22 / -12.79%
Volume 9.7M
ENZN On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Aby Buchbinder M.D.

Former Vice President of Clinical Development, Enzon Pharmaceuticals Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 1 different industries.

--$515,125
As of Fiscal Year 2013

Background*

Mr. Aby Buchbinder, M.D. served as the Vice President of Clinical Development at Enzon Pharmaceuticals Inc. since January 2006 to February 28, 2013.

Corporate Headquarters*

20 Kingsbridge Road
Piscataway, New Jersey 08854

United States

Phone: 732-980-4500
Fax: --

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

There is no Education data available.

Other Affiliations*

There is no Company Affiliations data available.

Annual Compensation*

Salary$91,044
Total Annual Compensation$91,044

Stock Options*

All Other Compensation$424,081
Exercisable Options53,000
Total Number of Options53,000

Total Compensation*

Total Annual Cash Compensation$515,125
Total Short Term Compensation$91,044
Other Long Term Compensation$424,081
Total Calculated Compensation$515,125
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENZN:US $1.50 USD -0.22

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
$831.2K
Judith Greciet Ph.D., PharmacyChief Executive Officer, Director and Member of Corporate Development Committee
Onxeo SA
€424.3K
William J. Polvino M.D.Chief Executive Officer and President
Veloxis Pharmaceuticals A/S
--
Daniel J. Abdun-Nabi Chief Executive Officer, President, Director, Member of Strategic Operations Committee and Member of Pricing Committee
Emergent BioSolutions, Inc.
$1.2M
William John Edward Burt DPhilChief Executive Officer and Executive Director
Abzena plc
--
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENZON PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.